Literature DB >> 15028765

Constitutive spinal cyclooxygenase-2 participates in the initiation of tissue injury-induced hyperalgesia.

Joseph R Ghilardi1, Camilla I Svensson, Scott D Rogers, Tony L Yaksh, Patrick W Mantyh.   

Abstract

Inhibitors of the isozyme cyclooxygenase-2 (COX-2) represent an important advance in pain management, although where and when these inhibitors can exert their antihyperalgesic actions are not completely understood. Here we show that unlike many peripheral tissues in which COX-2 is only expressed in physiologically significant levels after tissue injury, in the normal rat lumbar spinal cord, the majority of neurons and radial glia constitutively express high levels of COX-2 protein. Immediately after peripheral tissue injury and before any measurable upregulation of COX-2 protein in peripheral tissue or spinal cord, inhibition of constitutively expressed spinal COX-2 reduced injury-induced activation of primary afferent neurons, activation of spinal neurons, and the mechanical and thermal hyperalgesia that normally occurs after peripheral tissue injury. The present data demonstrate that constitutively expressed spinal COX-2 plays an important role in the initial hyperalgesia that follows peripheral tissue injury. These results suggest that blocking constitutive spinal COX-2 before tissue injury may reduce the initial peripheral and central sensitization that occurs after tissue injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15028765      PMCID: PMC6729511          DOI: 10.1523/JNEUROSCI.5054-03.2004

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  26 in total

1.  Pain control: breaking the circuit.

Authors:  S P Hunt
Journal:  Trends Pharmacol Sci       Date:  2000-08       Impact factor: 14.819

2.  Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons.

Authors:  M D Southall; M R Vasko
Journal:  J Biol Chem       Date:  2001-02-14       Impact factor: 5.157

3.  Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats.

Authors:  Z D Luo; S R Chaplan; E S Higuera; L S Sorkin; K A Stauderman; M E Williams; T L Yaksh
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

4.  Current pharmacotherapy of chronic pain.

Authors:  R K Portenoy
Journal:  J Pain Symptom Manage       Date:  2000-01       Impact factor: 3.612

5.  Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.

Authors:  E W Ehrich; A Dallob; I De Lepeleire; A Van Hecken; D Riendeau; W Yuan; A Porras; J Wittreich; J R Seibold; P De Schepper; D R Mehlisch; B J Gertz
Journal:  Clin Pharmacol Ther       Date:  1999-03       Impact factor: 6.875

Review 6.  Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents.

Authors:  A S Kalgutkar; Z Zhao
Journal:  Curr Drug Targets       Date:  2001-03       Impact factor: 3.465

7.  Substance P receptor (neurokinin-1)-expressing neurons in lamina I of the spinal cord encode for the intensity of noxious stimulation: a c-Fos study in rat.

Authors:  C A Doyle; S P Hunt
Journal:  Neuroscience       Date:  1999-03       Impact factor: 3.590

8.  Direct activation of rat spinal dorsal horn neurons by prostaglandin E2.

Authors:  H Baba; T Kohno; K A Moore; C J Woolf
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

9.  Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity.

Authors:  T A Samad; K A Moore; A Sapirstein; S Billet; A Allchorne; S Poole; J V Bonventre; C J Woolf
Journal:  Nature       Date:  2001-03-22       Impact factor: 49.962

10.  Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial.

Authors:  K Malmstrom; S Daniels; P Kotey; B C Seidenberg; P J Desjardins
Journal:  Clin Ther       Date:  1999-10       Impact factor: 3.393

View more
  36 in total

1.  Interactions of estradiol and NSAIDS on carrageenan-induced hyperalgesia.

Authors:  Deirtra A Hunter; Gordon A Barr; Kai-Yvonne Shivers; Nicole Amador; Shirzad Jenab; Charles Inturrisi; Vanya Quinones-Jenab
Journal:  Brain Res       Date:  2011-01-31       Impact factor: 3.252

2.  Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion.

Authors:  M Jakubowski; D Levy; V Kainz; X-C Zhang; B Kosaras; R Burstein
Journal:  Neuroscience       Date:  2007-07-25       Impact factor: 3.590

3.  Activation of NMDA receptor is associated with up-regulation of COX-2 expression in the spinal dorsal horn during nociceptive inputs in rats.

Authors:  Shu-Qin Li; Yan-Li Xing; Wei-Na Chen; Shu-Ling Yue; Li Li; Wen-Bin Li
Journal:  Neurochem Res       Date:  2009-04-01       Impact factor: 3.996

4.  The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors.

Authors:  J Guindon; J Desroches; P Beaulieu
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

5.  Chapter 9 The dorsal horn and hyperalgesia.

Authors:  Karin N Westlund
Journal:  Handb Clin Neurol       Date:  2006

Review 6.  A Double Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation.

Authors:  Rita Scarpelli; Oscar Sasso; Daniele Piomelli
Journal:  ChemMedChem       Date:  2015-10-21       Impact factor: 3.466

Review 7.  Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation.

Authors:  Daniel J Hermanson; Joyonna C Gamble-George; Lawrence J Marnett; Sachin Patel
Journal:  Trends Pharmacol Sci       Date:  2014-05-18       Impact factor: 14.819

8.  Localization of COX-1 and COX-2 in the intracranial dura mater of the rat.

Authors:  Xi-Chun Zhang; Vanessa Kainz; Moshe Jakubowski; Rami Burstein; Andrew Strassman; Dan Levy
Journal:  Neurosci Lett       Date:  2009-03-06       Impact factor: 3.046

9.  COX-2 expression and function in the hyperalgesic response to paw inflammation in mice.

Authors:  Naveen K Jain; Tomo-o Ishikawa; Igor Spigelman; Harvey R Herschman
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2008-10-01       Impact factor: 4.006

10.  Impact of central and peripheral TRPV1 and ROS levels on proinflammatory mediators and nociceptive behavior.

Authors:  Karin N Westlund; Mikhail Y Kochukov; Ying Lu; Terry A McNearney
Journal:  Mol Pain       Date:  2010-08-06       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.